Literature DB >> 20632194

Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial.

Yoshiyuki Narahara1, Hidenori Kanazawa, Takeshi Fukuda, Yoko Matsushita, Hirotomo Harimoto, Hideko Kidokoro, Tamaki Katakura, Masanori Atsukawa, Yasuhiko Taki, Yuu Kimura, Katsuhisa Nakatsuka, Choitsu Sakamoto.   

Abstract

BACKGROUND: Transjugular intrahepatic portosystemic shunt (TIPS) has recently been reported to be effective in the treatment of cirrhotic patients with refractory ascites. However, the clinical utility of TIPS in the subset of refractory ascitic patients with good hepatic and renal function is uncertain. The aim of this study was to compare the efficacy of TIPS to that of large-volume paracentesis in cirrhotic patients with refractory ascites who have good hepatic and renal function.
METHODS: Sixty cirrhotic patients with refractory ascites who presented with a Child-Pugh score of <11, serum bilirubin of <3 mg/dl and creatinine of <1.9 mg/dl were assigned randomly to TIPS (n = 30) or large-volume paracentesis plus albumin (n = 30). The primary endpoint was survival. The secondary endpoints were response to treatment and development of hepatic encephalopathy.
RESULTS: The baseline characteristics were similar in the two groups. Seventeen patients treated with TIPS and 21 treated with paracentesis died during the study period. The cumulative probabilities of survival at 1 and 2 years were 80 and 64% in the TIPS group and 49 and 35% in the paracentesis group (p < 0.005). TIPS was significantly superior to paracentesis in the control of ascites (p < 0.005). Treatment failure was more frequent in the paracentesis group, whereas the frequency of hepatic encephalopathy was greater in the TIPS group.
CONCLUSIONS: In cirrhotic patients with refractory ascites who have good hepatic and renal function, TIPS improves survival and provides better control of ascites than large-volume paracentesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20632194     DOI: 10.1007/s00535-010-0282-9

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  31 in total

Review 1.  Transjugular intrahepatic portosystemic shunt: present status, comparison with endoscopic therapy and shunt surgery, and future prospectives.

Authors:  J Rösch; F S Keller
Journal:  World J Surg       Date:  2001-04-11       Impact factor: 3.352

2.  Uncovered transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis.

Authors:  Gennaro D'Amico; Angelo Luca; Alberto Morabito; Roberto Miraglia; Mario D'Amico
Journal:  Gastroenterology       Date:  2005-10       Impact factor: 22.682

3.  Refractory ascites: midterm results of treatment with a transjugular intrahepatic portosystemic shunt.

Authors:  G K Nazarian; H Bjarnason; C A Dietz; C A Bernadas; M C Foshager; H Ferral; D W Hunter
Journal:  Radiology       Date:  1997-10       Impact factor: 11.105

4.  A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites.

Authors:  Agustín Albillos; Rafael Bañares; Mónica González; María-Vega Catalina; Luis-Miguel Molinero
Journal:  J Hepatol       Date:  2005-07-05       Impact factor: 25.083

5.  Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: effect on clinical, renal, humoral, and hemodynamic parameters.

Authors:  J Quiroga; B Sangro; M Núñez; I Bilbao; J Longo; L García-Villarreal; J M Zozaya; M Betés; J I Herrero; J Prieto
Journal:  Hepatology       Date:  1995-04       Impact factor: 17.425

Review 6.  Management of refractory ascites and hepatorenal syndrome.

Authors:  Anuchit Chutaputti
Journal:  J Gastroenterol Hepatol       Date:  2002-04       Impact factor: 4.029

Review 7.  Transjugular intrahepatic portosystemic shunt in the management of ascites and hepatorenal syndrome.

Authors:  Marco Senzolo; Evangelos Cholongitas; Jonathan Tibballs; Andrew Burroughs; David Patch
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-11       Impact factor: 2.566

8.  Cardiovascular, renal, and neurohumoral responses to single large-volume paracentesis in patients with cirrhosis and diuretic-resistant ascites.

Authors:  K M Peltekian; F Wong; P P Liu; A G Logan; M Sherman; L M Blendis
Journal:  Am J Gastroenterol       Date:  1997-03       Impact factor: 10.864

9.  Transjugular intrahepatic portosystemic shunts for refractory ascites: assessment of clinical and hormonal response and renal function.

Authors:  K A Somberg; J R Lake; S J Tomlanovich; J M LaBerge; V Feldstein; N M Bass
Journal:  Hepatology       Date:  1995-03       Impact factor: 17.425

10.  Clinical characteristics and outcome of patients with cirrhosis and refractory ascites.

Authors:  Richard Moreau; Paul Delègue; Fabienne Pessione; Sophie Hillaire; François Durand; Didier Lebrec; Dominique-Charles Valla
Journal:  Liver Int       Date:  2004-10       Impact factor: 5.828

View more
  38 in total

1.  Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.

Authors:  Ai Nakagawa; Masanori Atsukawa; Akihito Tsubota; Chisa Kondo; Tomomi Okubo; Taeang Arai; Norio Itokawa; Yoshiyuki Narahara; Katsuhiko Iwakiri
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 2.  Transjugular intrahepatic portosystemic shunt: An overview.

Authors:  Harjit K Bhogal; Arun J Sanyal
Journal:  Clin Liver Dis (Hoboken)       Date:  2012-11-09

3.  Parallel TIPS for treatment of refractory ascites and hepatic hydrothorax.

Authors:  Ahmad Parvinian; Ron C Gaba
Journal:  Dig Dis Sci       Date:  2013-04-27       Impact factor: 3.199

Review 4.  Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review.

Authors:  Xing-Shun Qi; Ming Bai; Zhi-Ping Yang; Dai-Ming Fan
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

5.  Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites.

Authors:  Ahmad Parvinian; James T Bui; M Grace Knuttinen; Jeet Minocha; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

Review 6.  Transjugular intrahepatic portosystemic shunt.

Authors:  Kavish R Patidar; Malcolm Sydnor; Arun J Sanyal
Journal:  Clin Liver Dis       Date:  2014-08-27       Impact factor: 6.126

Review 7.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

8.  Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis.

Authors:  Hauke S Heinzow; Philipp Lenz; Michael Köhler; Frank Reinecke; Hansjörg Ullerich; Wolfram Domschke; Dirk Domagk; Tobias Meister
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

Review 9.  Outcomes of transjugular intrahepatic portosystemic shunts for ascites.

Authors:  Zachary L Bercu; Aaron M Fischman
Journal:  Semin Intervent Radiol       Date:  2014-09       Impact factor: 1.513

Review 10.  Transjugular Intrahepatic Portosystemic Shunt Placement for Refractory Ascites: Review and Update of the Literature.

Authors:  Ana Cecilia Burgos; Bartley Thornburg
Journal:  Semin Intervent Radiol       Date:  2018-08-06       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.